Type 2 Diabetes as a Determinant of Parkinson's Disease Risk and Progression
Background Type 2 diabetes (T2DM) and Parkinson's disease (PD) are prevalent diseases that affect an aging population. Previous systematic reviews and meta‐analyses have explored the relationship between diabetes and the risk of PD, but the results have been conflicting. Objective The objective...
Gespeichert in:
| Veröffentlicht in: | Movement disorders Jg. 36; H. 6; S. 1420 - 1429 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Journal Article |
| Sprache: | Englisch |
| Veröffentlicht: |
Hoboken, USA
John Wiley & Sons, Inc
01.06.2021
Wiley Subscription Services, Inc |
| Schlagworte: | |
| ISSN: | 0885-3185, 1531-8257, 1531-8257 |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| Abstract | Background
Type 2 diabetes (T2DM) and Parkinson's disease (PD) are prevalent diseases that affect an aging population. Previous systematic reviews and meta‐analyses have explored the relationship between diabetes and the risk of PD, but the results have been conflicting.
Objective
The objective was to investigate T2DM as a determinant of PD through a meta‐analysis of observational and genetic summary data.
Methods
A systematic review and meta‐analysis of observational studies was undertaken by searching 6 databases. We selected the highest‐quality studies investigating the association of T2DM with PD risk and progression. We then used Mendelian randomization (MR) to investigate the causal effects of genetic liability toward T2DM on PD risk and progression, using summary data derived from genome‐wide association studies.
Results
In the observational part of the study, pooled effect estimates showed that T2DM was associated with an increased risk of PD (odds ratio [OR] 1.21, 95% confidence interval [CI] 1.07–1.36), and there was some evidence that T2DM was associated with faster progression of motor symptoms (standardized mean difference [SMD] 0.55, 95% CI 0.39–0.72) and cognitive decline (SMD −0.92, 95% CI −1.50 to −0.34). Using MR, we found supportive evidence for a causal effect of diabetes on PD risk (inverse‐variance weighted method [IVW] OR 1.08, 95% CI 1.02–1.14; P = 0.010) and some evidence of an effect on motor progression (IVW OR 1.10, 95% CI 1.01–1.20; P = 0.032) but not on cognitive progression.
Conclusions
Using meta‐analyses of traditional observational studies and genetic data, we observed convincing evidence for an effect of T2DM on PD risk and new evidence to support a role in PD progression. © 2021 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society |
|---|---|
| AbstractList | BackgroundType 2 diabetes (T2DM) and Parkinson's disease (PD) are prevalent diseases that affect an aging population. Previous systematic reviews and meta‐analyses have explored the relationship between diabetes and the risk of PD, but the results have been conflicting.ObjectiveThe objective was to investigate T2DM as a determinant of PD through a meta‐analysis of observational and genetic summary data.MethodsA systematic review and meta‐analysis of observational studies was undertaken by searching 6 databases. We selected the highest‐quality studies investigating the association of T2DM with PD risk and progression. We then used Mendelian randomization (MR) to investigate the causal effects of genetic liability toward T2DM on PD risk and progression, using summary data derived from genome‐wide association studies.ResultsIn the observational part of the study, pooled effect estimates showed that T2DM was associated with an increased risk of PD (odds ratio [OR] 1.21, 95% confidence interval [CI] 1.07–1.36), and there was some evidence that T2DM was associated with faster progression of motor symptoms (standardized mean difference [SMD] 0.55, 95% CI 0.39–0.72) and cognitive decline (SMD −0.92, 95% CI −1.50 to −0.34). Using MR, we found supportive evidence for a causal effect of diabetes on PD risk (inverse‐variance weighted method [IVW] OR 1.08, 95% CI 1.02–1.14; P = 0.010) and some evidence of an effect on motor progression (IVW OR 1.10, 95% CI 1.01–1.20; P = 0.032) but not on cognitive progression.ConclusionsUsing meta‐analyses of traditional observational studies and genetic data, we observed convincing evidence for an effect of T2DM on PD risk and new evidence to support a role in PD progression. © 2021 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society Type 2 diabetes (T2DM) and Parkinson's disease (PD) are prevalent diseases that affect an aging population. Previous systematic reviews and meta-analyses have explored the relationship between diabetes and the risk of PD, but the results have been conflicting.BACKGROUNDType 2 diabetes (T2DM) and Parkinson's disease (PD) are prevalent diseases that affect an aging population. Previous systematic reviews and meta-analyses have explored the relationship between diabetes and the risk of PD, but the results have been conflicting.The objective was to investigate T2DM as a determinant of PD through a meta-analysis of observational and genetic summary data.OBJECTIVEThe objective was to investigate T2DM as a determinant of PD through a meta-analysis of observational and genetic summary data.A systematic review and meta-analysis of observational studies was undertaken by searching 6 databases. We selected the highest-quality studies investigating the association of T2DM with PD risk and progression. We then used Mendelian randomization (MR) to investigate the causal effects of genetic liability toward T2DM on PD risk and progression, using summary data derived from genome-wide association studies.METHODSA systematic review and meta-analysis of observational studies was undertaken by searching 6 databases. We selected the highest-quality studies investigating the association of T2DM with PD risk and progression. We then used Mendelian randomization (MR) to investigate the causal effects of genetic liability toward T2DM on PD risk and progression, using summary data derived from genome-wide association studies.In the observational part of the study, pooled effect estimates showed that T2DM was associated with an increased risk of PD (odds ratio [OR] 1.21, 95% confidence interval [CI] 1.07-1.36), and there was some evidence that T2DM was associated with faster progression of motor symptoms (standardized mean difference [SMD] 0.55, 95% CI 0.39-0.72) and cognitive decline (SMD -0.92, 95% CI -1.50 to -0.34). Using MR, we found supportive evidence for a causal effect of diabetes on PD risk (inverse-variance weighted method [IVW] OR 1.08, 95% CI 1.02-1.14; P = 0.010) and some evidence of an effect on motor progression (IVW OR 1.10, 95% CI 1.01-1.20; P = 0.032) but not on cognitive progression.RESULTSIn the observational part of the study, pooled effect estimates showed that T2DM was associated with an increased risk of PD (odds ratio [OR] 1.21, 95% confidence interval [CI] 1.07-1.36), and there was some evidence that T2DM was associated with faster progression of motor symptoms (standardized mean difference [SMD] 0.55, 95% CI 0.39-0.72) and cognitive decline (SMD -0.92, 95% CI -1.50 to -0.34). Using MR, we found supportive evidence for a causal effect of diabetes on PD risk (inverse-variance weighted method [IVW] OR 1.08, 95% CI 1.02-1.14; P = 0.010) and some evidence of an effect on motor progression (IVW OR 1.10, 95% CI 1.01-1.20; P = 0.032) but not on cognitive progression.Using meta-analyses of traditional observational studies and genetic data, we observed convincing evidence for an effect of T2DM on PD risk and new evidence to support a role in PD progression. © 2021 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.CONCLUSIONSUsing meta-analyses of traditional observational studies and genetic data, we observed convincing evidence for an effect of T2DM on PD risk and new evidence to support a role in PD progression. © 2021 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society. Type 2 diabetes (T2DM) and Parkinson's disease (PD) are prevalent diseases that affect an aging population. Previous systematic reviews and meta-analyses have explored the relationship between diabetes and the risk of PD, but the results have been conflicting. The objective was to investigate T2DM as a determinant of PD through a meta-analysis of observational and genetic summary data. A systematic review and meta-analysis of observational studies was undertaken by searching 6 databases. We selected the highest-quality studies investigating the association of T2DM with PD risk and progression. We then used Mendelian randomization (MR) to investigate the causal effects of genetic liability toward T2DM on PD risk and progression, using summary data derived from genome-wide association studies. In the observational part of the study, pooled effect estimates showed that T2DM was associated with an increased risk of PD (odds ratio [OR] 1.21, 95% confidence interval [CI] 1.07-1.36), and there was some evidence that T2DM was associated with faster progression of motor symptoms (standardized mean difference [SMD] 0.55, 95% CI 0.39-0.72) and cognitive decline (SMD -0.92, 95% CI -1.50 to -0.34). Using MR, we found supportive evidence for a causal effect of diabetes on PD risk (inverse-variance weighted method [IVW] OR 1.08, 95% CI 1.02-1.14; P = 0.010) and some evidence of an effect on motor progression (IVW OR 1.10, 95% CI 1.01-1.20; P = 0.032) but not on cognitive progression. Using meta-analyses of traditional observational studies and genetic data, we observed convincing evidence for an effect of T2DM on PD risk and new evidence to support a role in PD progression. © 2021 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society. Background Type 2 diabetes (T2DM) and Parkinson's disease (PD) are prevalent diseases that affect an aging population. Previous systematic reviews and meta‐analyses have explored the relationship between diabetes and the risk of PD, but the results have been conflicting. Objective The objective was to investigate T2DM as a determinant of PD through a meta‐analysis of observational and genetic summary data. Methods A systematic review and meta‐analysis of observational studies was undertaken by searching 6 databases. We selected the highest‐quality studies investigating the association of T2DM with PD risk and progression. We then used Mendelian randomization (MR) to investigate the causal effects of genetic liability toward T2DM on PD risk and progression, using summary data derived from genome‐wide association studies. Results In the observational part of the study, pooled effect estimates showed that T2DM was associated with an increased risk of PD (odds ratio [OR] 1.21, 95% confidence interval [CI] 1.07–1.36), and there was some evidence that T2DM was associated with faster progression of motor symptoms (standardized mean difference [SMD] 0.55, 95% CI 0.39–0.72) and cognitive decline (SMD −0.92, 95% CI −1.50 to −0.34). Using MR, we found supportive evidence for a causal effect of diabetes on PD risk (inverse‐variance weighted method [IVW] OR 1.08, 95% CI 1.02–1.14; P = 0.010) and some evidence of an effect on motor progression (IVW OR 1.10, 95% CI 1.01–1.20; P = 0.032) but not on cognitive progression. Conclusions Using meta‐analyses of traditional observational studies and genetic data, we observed convincing evidence for an effect of T2DM on PD risk and new evidence to support a role in PD progression. © 2021 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society |
| Author | Jacobs, Benjamin M. Bandres Ciga, Sara Bestwick, Jonathan P. Noyce, Alastair J. Chohan, Harneek Senkevich, Konstantin Gan‐Or, Ziv Patel, Radhika K. |
| AuthorAffiliation | 2 Department of Neurology and Neurosurgery, McGill University, Montréal, Quebec, Canada 5 Department of Human Genetics, McGill University, Montréal, Quebec, Canada 1 Preventive Neurology Unit, Wolfson Institute of Preventive Medicine, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, UK 6 Department of Clinical and Movement Neurosciences, UCL Institute of Neurology, London, UK 3 Montreal Neurological Institute, McGill University, Montréal, Quebec, Canada 4 Molecular Genetics Section, Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda, Maryland, USA |
| AuthorAffiliation_xml | – name: 2 Department of Neurology and Neurosurgery, McGill University, Montréal, Quebec, Canada – name: 1 Preventive Neurology Unit, Wolfson Institute of Preventive Medicine, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, UK – name: 3 Montreal Neurological Institute, McGill University, Montréal, Quebec, Canada – name: 6 Department of Clinical and Movement Neurosciences, UCL Institute of Neurology, London, UK – name: 4 Molecular Genetics Section, Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda, Maryland, USA – name: 5 Department of Human Genetics, McGill University, Montréal, Quebec, Canada |
| Author_xml | – sequence: 1 givenname: Harneek orcidid: 0000-0003-0561-758X surname: Chohan fullname: Chohan, Harneek organization: Queen Mary University of London – sequence: 2 givenname: Konstantin surname: Senkevich fullname: Senkevich, Konstantin organization: McGill University – sequence: 3 givenname: Radhika K. surname: Patel fullname: Patel, Radhika K. organization: Queen Mary University of London – sequence: 4 givenname: Jonathan P. surname: Bestwick fullname: Bestwick, Jonathan P. organization: Queen Mary University of London – sequence: 5 givenname: Benjamin M. surname: Jacobs fullname: Jacobs, Benjamin M. organization: Queen Mary University of London – sequence: 6 givenname: Sara surname: Bandres Ciga fullname: Bandres Ciga, Sara organization: National Institute on Aging, National Institutes of Health – sequence: 7 givenname: Ziv surname: Gan‐Or fullname: Gan‐Or, Ziv organization: McGill University – sequence: 8 givenname: Alastair J. orcidid: 0000-0003-3027-5497 surname: Noyce fullname: Noyce, Alastair J. email: a.noyce@qmul.ac.uk organization: UCL Institute of Neurology |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/33682937$$D View this record in MEDLINE/PubMed |
| BookMark | eNp1kV9PFDEUxRuDkQV98AuQJj6IDwv9M-10XkjMLoLJGonic9OZuYOFmXbtnZXst6e6iwGCSZM26e-enHvOHtkJMQAhbzk74oyJ46HFI2GU4i_IhCvJp0aocodMmDFqKrlRu2QP8ZoxzhXXr8iulNqISpYTsrhcL4EKOveuhhGQunzoPD_T4IMLI40dvXDpxgeM4T1mEMEh0G8eb6gLLb1I8SoBoo_hNXnZuR7hzfbeJz8-nV7OzqeLr2efZx8X06YosjsJCkqnnJAF64xsHRSVaWulmwKE4Uo1WmlVV4bV2a6TXdOaCrTouNGlNEbuk5ON7nJVD9A2EMbkertMfnBpbaPz9vFP8D_tVfxtK8bLnEcWONwKpPhrBTjawWMDfe8CxBVakQ1VlS41y-i7J-h1XKWQ17NCFYJXPIeZqYOHjv5ZuQ86A8cboEkRMUFnGz-6MYeWDfrecmb_VGlzlfZvlXniw5OJe9Hn2K36re9h_X_Qfpl_30zcAdqXq9Q |
| CitedBy_id | crossref_primary_10_1002_hsr2_70126 crossref_primary_10_1016_j_pnpbp_2024_111128 crossref_primary_10_12688_f1000research_27413_3 crossref_primary_10_12688_f1000research_27413_2 crossref_primary_10_1038_s41531_025_01100_1 crossref_primary_10_3233_JPD_212611 crossref_primary_10_1016_j_arr_2022_101727 crossref_primary_10_1002_mds_29009 crossref_primary_10_1038_s41531_025_00941_0 crossref_primary_10_1016_j_molmed_2023_09_005 crossref_primary_10_3390_ijms25084358 crossref_primary_10_3390_ijms252212409 crossref_primary_10_1038_s41598_025_96382_z crossref_primary_10_1016_j_neuron_2023_03_021 crossref_primary_10_1038_s41531_025_00983_4 crossref_primary_10_3233_JPD_223180 crossref_primary_10_1007_s11910_024_01339_w crossref_primary_10_1002_mds_29122 crossref_primary_10_1038_s41531_024_00739_6 crossref_primary_10_1002_ana_26852 crossref_primary_10_3389_fneur_2022_1035721 crossref_primary_10_1016_j_tins_2024_01_002 crossref_primary_10_3390_biomedicines12122841 crossref_primary_10_3233_JPD_240019 crossref_primary_10_3390_life15060936 crossref_primary_10_1002_mdc3_13893 crossref_primary_10_2174_0115743624334102241115162404 crossref_primary_10_3390_ijms23158281 crossref_primary_10_1002_acn3_51913 crossref_primary_10_1186_s13098_024_01299_8 crossref_primary_10_1016_j_jtice_2024_105401 crossref_primary_10_1016_j_ncl_2024_12_003 crossref_primary_10_3389_fneur_2023_1174698 crossref_primary_10_1002_mds_28829 crossref_primary_10_1007_s10654_023_00970_0 crossref_primary_10_1038_s41598_024_53287_7 crossref_primary_10_1177_1877718X251367305 crossref_primary_10_1093_braincomms_fcaf325 crossref_primary_10_3390_cells13221876 crossref_primary_10_1093_ageing_afaf220 crossref_primary_10_3233_JPD_223454 crossref_primary_10_32604_biocell_2024_056272 crossref_primary_10_1097_ANA_0000000000000985 crossref_primary_10_1002_mdc3_14031 crossref_primary_10_1016_j_parkreldis_2021_11_033 crossref_primary_10_1038_s41598_024_53196_9 crossref_primary_10_1073_pnas_2207273119 crossref_primary_10_1098_rsob_240239 crossref_primary_10_3390_biomedicines11112993 crossref_primary_10_1016_j_jpha_2022_11_006 crossref_primary_10_3390_cells14100710 crossref_primary_10_1007_s13760_023_02424_6 crossref_primary_10_1016_j_jmb_2022_167927 crossref_primary_10_1016_j_pneurobio_2023_102462 crossref_primary_10_1002_mds_29708 crossref_primary_10_1093_nutrit_nuae208 crossref_primary_10_3389_fnagi_2022_853372 crossref_primary_10_1016_j_brainres_2025_149738 crossref_primary_10_1002_mds_29424 crossref_primary_10_1093_brain_awad265 crossref_primary_10_3390_ph18050630 crossref_primary_10_1002_ana_26458 crossref_primary_10_1055_s_0045_1805075 crossref_primary_10_1371_journal_pone_0262464 crossref_primary_10_1016_j_jns_2023_120851 crossref_primary_10_1038_s41598_025_07735_7 crossref_primary_10_1177_1877718X251359391 crossref_primary_10_3389_fneur_2021_706145 crossref_primary_10_1002_alz_70639 crossref_primary_10_3390_nu14142781 crossref_primary_10_1016_j_clnesp_2024_02_018 crossref_primary_10_1038_s41392_025_02145_7 crossref_primary_10_1097_WNR_0000000000002123 crossref_primary_10_1007_s11055_023_01488_4 crossref_primary_10_1016_j_parkreldis_2023_105881 crossref_primary_10_1002_mds_28689 crossref_primary_10_1097_MD_0000000000035241 crossref_primary_10_1002_ana_26467 crossref_primary_10_1016_j_dscb_2022_100048 crossref_primary_10_1186_s12964_023_01328_5 crossref_primary_10_3390_nu14153240 crossref_primary_10_3390_ijms26020542 crossref_primary_10_1093_hmg_ddac205 crossref_primary_10_1126_sciadv_adu2937 crossref_primary_10_1002_brb3_2838 crossref_primary_10_1155_2023_7887792 crossref_primary_10_1016_j_lana_2025_101046 crossref_primary_10_1016_j_jocn_2023_10_013 crossref_primary_10_1016_j_psyneuen_2025_107444 crossref_primary_10_1080_14728222_2022_2079492 crossref_primary_10_1111_bph_15508 crossref_primary_10_3390_jcm13020561 crossref_primary_10_1111_bcp_16035 crossref_primary_10_3389_fnagi_2025_1548020 crossref_primary_10_1007_s11684_024_1116_0 crossref_primary_10_1016_j_parkreldis_2024_107026 crossref_primary_10_31083_RN38630 crossref_primary_10_3389_fmed_2021_800973 crossref_primary_10_1016_j_expneurol_2025_115137 crossref_primary_10_3390_ijms222212346 crossref_primary_10_1016_j_dscb_2024_100158 crossref_primary_10_1038_s41531_021_00255_x crossref_primary_10_1016_j_isci_2024_110235 crossref_primary_10_1212_WNL_0000000000201468 crossref_primary_10_1007_s00415_024_12207_5 crossref_primary_10_1016_j_neuropharm_2021_108839 crossref_primary_10_1038_s41531_024_00711_4 crossref_primary_10_1016_j_brainresbull_2023_110672 crossref_primary_10_3390_jpm12121994 crossref_primary_10_1515_revneuro_2022_0093 crossref_primary_10_1016_j_cca_2023_117682 crossref_primary_10_3233_JPD_230104 crossref_primary_10_3389_fendo_2023_1196293 crossref_primary_10_1016_j_jep_2024_119095 crossref_primary_10_1038_s41531_022_00374_z crossref_primary_10_3390_jcm14134679 crossref_primary_10_1007_s10654_023_01013_4 crossref_primary_10_1007_s10072_023_07273_y crossref_primary_10_3389_fnagi_2023_1211990 crossref_primary_10_1177_17562864251330251 crossref_primary_10_1007_s00221_023_06605_w crossref_primary_10_1016_j_diabres_2025_112914 crossref_primary_10_3390_pharmaceutics16040514 crossref_primary_10_1007_s00415_022_11496_y crossref_primary_10_1002_mds_30276 crossref_primary_10_1007_s12149_022_01818_5 crossref_primary_10_1111_cns_70487 crossref_primary_10_1002_mds_29333 crossref_primary_10_1016_j_jocn_2022_10_023 crossref_primary_10_1155_2023_7427136 crossref_primary_10_3390_ijms23158060 crossref_primary_10_1002_mds_29298 crossref_primary_10_1038_s41531_025_01010_2 crossref_primary_10_1111_ene_70290 |
| Cites_doi | 10.3233/JPD-191763 10.1002/mds.20685 10.1073/pnas.1610371113 10.1016/j.parkreldis.2005.09.004 10.1212/WNL.0000000000005771 10.1093/ije/dyu005 10.1038/s41588-020-0637-y 10.2337/dc06-2011 10.1002/ana.23687 10.1093/brain/awaa262 10.1038/nrendo.2011.138 10.1371/journal.pmed.1002314 10.1002/mds.23855 10.1038/s41588-018-0099-7 10.1136/jnnp-2020-323646 10.1371/journal.pone.0085781 10.1111/j.1600-0404.1994.tb01655.x 10.1002/mds.26698 10.1097/MD.0000000000003549 10.1111/ane.12793 10.1038/nrendo.2017.151 10.1016/S1474-4422(19)30320-5 10.1136/bmj.b2535 10.1001/jamaneurol.2019.3419 10.1016/S0140-6736(17)31585-4 10.2337/dc08-0688 10.1093/hmg/ddy327 10.1093/oxfordjournals.aje.a116960 10.1101/253690 10.2337/dc11-1511 10.1016/j.pneurobio.2016.10.001 10.1016/j.parkreldis.2012.07.003 10.1002/1097-0258(20001130)19:22<3127::AID-SIM784>3.0.CO;2-M 10.1017/S0317167100052835 10.1093/ije/dyv080 10.1111/j.1471-4159.2004.02949.x 10.1093/oxfordjournals.aje.a121455 10.1002/mds.25016 10.1016/j.parkreldis.2009.02.013 10.1016/j.jns.2017.04.010 10.2337/dc11-1584 10.1093/ije/dyl263 10.1212/WNL.0b013e3182553cc9 10.1002/mds.27845 10.3389/fnins.2018.00073 10.3389/fnins.2020.547175 10.1093/ije/dyr036 10.1002/sim.3034 10.1016/j.diabet.2020.08.006 10.1097/EDE.0000000000000559 10.1001/archneur.64.4.570 10.1097/MD.0000000000005921 10.2337/dc10-1922 10.1007/s10654-010-9491-z 10.1016/j.jns.2010.03.002 10.1212/01.wnl.0000271883.45010.8a 10.2337/dc10-1333 10.3233/JPD-191900 10.1136/pgmj.2004.029124 10.2147/DMSO.S100074 10.1093/ije/dyy258 10.1212/WNL.0000000000005475 10.1371/journal.pgen.1007081 10.7554/eLife.34408 10.1212/WNL.0b013e3181c06635 |
| ContentType | Journal Article |
| Copyright | 2021 The Authors. published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society 2021 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society. 2021. This article is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| Copyright_xml | – notice: 2021 The Authors. published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society – notice: 2021 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society. – notice: 2021. This article is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| DBID | 24P AAYXX CITATION CGR CUY CVF ECM EIF NPM 7TK 8FD FR3 K9. NAPCQ P64 RC3 7X8 5PM |
| DOI | 10.1002/mds.28551 |
| DatabaseName | Wiley Online Library Open Access CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Neurosciences Abstracts Technology Research Database Engineering Research Database ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Premium Biotechnology and BioEngineering Abstracts Genetics Abstracts MEDLINE - Academic PubMed Central (Full Participant titles) |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Nursing & Allied Health Premium Genetics Abstracts Technology Research Database ProQuest Health & Medical Complete (Alumni) Engineering Research Database Neurosciences Abstracts Biotechnology and BioEngineering Abstracts MEDLINE - Academic |
| DatabaseTitleList | Nursing & Allied Health Premium MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: 24P name: Wiley Online Library Open Access url: https://authorservices.wiley.com/open-science/open-access/browse-journals.html sourceTypes: Publisher – sequence: 2 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1531-8257 |
| EndPage | 1429 |
| ExternalDocumentID | PMC9017318 33682937 10_1002_mds_28551 MDS28551 |
| Genre | article Meta-Analysis Research Support, N.I.H., Intramural Research Support, Non-U.S. Gov't Systematic Review Journal Article |
| GrantInformation_xml | – fundername: Fonds de recherche du Québec—Santé (FRQS) – fundername: Canada First Research Excellence Fund (CFREF) – fundername: Intramural Research Program of the NIH, National Institute on Aging – fundername: Young Investigator Award by Parkinson Canada – fundername: Canadian Consortium on Neurodegeneration in Aging (CCNA) – fundername: The Barts Charity – fundername: Michael J. Fox Foundation – fundername: Intramural NIH HHS grantid: Z99 AG999999 – fundername: Fonds de recherche du Québec-Santé (FRQS) |
| GroupedDBID | --- .3N .GA .GJ .Y3 05W 0R~ 10A 123 1CY 1L6 1OB 1OC 1ZS 24P 31~ 33P 3PY 3SF 3WU 4.4 4ZD 50Y 50Z 51W 51X 52M 52N 52O 52P 52R 52S 52T 52U 52V 52W 52X 53G 5VS 66C 6PF 702 7PT 8-0 8-1 8-3 8-4 8-5 8UM 930 A01 A03 AAESR AAEVG AAHHS AAHQN AAIPD AAMNL AANHP AANLZ AAONW AASGY AAWTL AAXRX AAYCA AAZKR ABCQN ABCUV ABEML ABIJN ABJNI ABLJU ABPVW ABQWH ABXGK ACAHQ ACBWZ ACCFJ ACCZN ACGFS ACGOF ACMXC ACPOU ACPRK ACRPL ACSCC ACXBN ACXQS ACYXJ ADBBV ADBTR ADEOM ADIZJ ADKYN ADMGS ADNMO ADOZA ADXAS ADZMN AEEZP AEIGN AEIMD AENEX AEQDE AEUQT AEUYR AFBPY AFFPM AFGKR AFPWT AFWVQ AFZJQ AHBTC AHMBA AIACR AITYG AIURR AIWBW AJBDE ALAGY ALMA_UNASSIGNED_HOLDINGS ALUQN ALVPJ AMBMR AMYDB ASPBG ATUGU AVWKF AZBYB AZFZN AZVAB BAFTC BDRZF BFHJK BHBCM BMXJE BROTX BRXPI BY8 C45 CS3 D-6 D-7 D-E D-F DCZOG DPXWK DR1 DR2 DRFUL DRMAN DRSTM DU5 EBD EBS EJD EMOBN F00 F01 F04 F5P FEDTE FUBAC FYBCS G-S G.N GNP GODZA H.X HBH HF~ HGLYW HHY HHZ HVGLF HZ~ IX1 J0M JPC KBYEO KQQ LATKE LAW LC2 LC3 LEEKS LH4 LITHE LOXES LP6 LP7 LUTES LW6 LYRES M6M MEWTI MK4 MRFUL MRMAN MRSTM MSFUL MSMAN MSSTM MXFUL MXMAN MXSTM N04 N05 N9A NF~ NNB O66 O9- OIG OVD P2P P2W P2X P2Z P4B P4D PALCI PQQKQ Q.N Q11 QB0 QRW R.K RIWAO RJQFR ROL RWD RWI RX1 RYL SAMSI SUPJJ SV3 TEORI TWZ UB1 V2E V9Y W8V W99 WBKPD WHWMO WIB WIH WIJ WIK WJL WOHZO WQJ WRC WUP WVDHM WXI WXSBR XG1 XV2 YCJ ZGI ZZTAW ~IA ~WT AAMMB AAYXX AEFGJ AEYWJ AGHNM AGQPQ AGXDD AGYGG AIDQK AIDYY AIQQE CITATION O8X CGR CUY CVF ECM EIF NPM 7TK 8FD FR3 K9. NAPCQ P64 RC3 7X8 5PM |
| ID | FETCH-LOGICAL-c4431-3e5e7a5a2340f83dae498db56c4e28155c6565b980b516a3fcd89e62f18673883 |
| IEDL.DBID | 24P |
| ISICitedReferencesCount | 156 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000626100900001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 0885-3185 1531-8257 |
| IngestDate | Tue Nov 04 01:49:42 EST 2025 Thu Jul 10 23:19:24 EDT 2025 Sat Nov 29 15:07:06 EST 2025 Mon Jul 21 05:35:56 EDT 2025 Sat Nov 29 07:11:01 EST 2025 Tue Nov 18 21:52:29 EST 2025 Wed Jan 22 16:29:09 EST 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 6 |
| Keywords | Parkinson's disease type 2 diabetes |
| Language | English |
| License | Attribution 2021 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society. This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c4431-3e5e7a5a2340f83dae498db56c4e28155c6565b980b516a3fcd89e62f18673883 |
| Notes | Z.G.‐O. received consultancy fees from Lysosomal Therapeutics Inc. (LTI), Idorsia, Prevail Therapeutics, Inceptions Sciences (now Ventus), Ono Therapeutics, Neuron23, Handl Therapeutics, Denali, and Deerfield. A.J.N. reports grants from the Barts Charity, Parkinson's UK, Aligning Science Across Parkinson's and Michael J. Fox Foundation, and the Virginia Keiley Benefaction. Personal fees/honoraria from Britannia, BIAL, AbbVie, Global Kinetics Corporation, Profile, Biogen, Roche, and UCB are outside of the submitted work. Relevant conflicts of interest/financial disclosures H.C. and K.S. contributed equally to this work. ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 ObjectType-Undefined-3 |
| ORCID | 0000-0003-3027-5497 0000-0003-0561-758X |
| OpenAccessLink | https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fmds.28551 |
| PMID | 33682937 |
| PQID | 2542191336 |
| PQPubID | 1016421 |
| PageCount | 10 |
| ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_9017318 proquest_miscellaneous_2498996760 proquest_journals_2542191336 pubmed_primary_33682937 crossref_citationtrail_10_1002_mds_28551 crossref_primary_10_1002_mds_28551 wiley_primary_10_1002_mds_28551_MDS28551 |
| PublicationCentury | 2000 |
| PublicationDate | June 2021 |
| PublicationDateYYYYMMDD | 2021-06-01 |
| PublicationDate_xml | – month: 06 year: 2021 text: June 2021 |
| PublicationDecade | 2020 |
| PublicationPlace | Hoboken, USA |
| PublicationPlace_xml | – name: Hoboken, USA – name: United States – name: Hoboken |
| PublicationTitle | Movement disorders |
| PublicationTitleAlternate | Mov Disord |
| PublicationYear | 2021 |
| Publisher | John Wiley & Sons, Inc Wiley Subscription Services, Inc |
| Publisher_xml | – name: John Wiley & Sons, Inc – name: Wiley Subscription Services, Inc |
| References | 2019; 2019 1994; 139 2016; 145‐146 2016; 31 2017; 390 2019; 18 2020; 14 2020; 10 2008; 31 2007; 30 2007; 36 2012; 72 2018; 7 2013; 19 2000; 19 2010; 25 2020; 52 2006; 21 2008; 27 2015; 44 2020; 91 2019; 28 2016; 113 2011; 26 1972; 96 2012; 27 2014; 9 2007; 64 2009; 15 2007; 69 2006; 12 2017; 28 2020; 143 2019; 34 2011; 40 1994; 89 2016; 95 2011; 34 2005; 81 2020; 77 2001; 28 2009; 339 2012; 35 2012; 78 2017; 377 2017; 136 2011; 8 2014; 43 2017; 96 2009; 73 2017; 14 2020 2017; 10 2017; 13 2019; 48 2018; 91 2018 2018; 90 2010; 293 2018; 50 2005; 93 2018; 12 2018; 14 e_1_2_8_28_1 e_1_2_8_24_1 e_1_2_8_47_1 e_1_2_8_26_1 e_1_2_8_49_1 e_1_2_8_3_1 e_1_2_8_5_1 e_1_2_8_7_1 e_1_2_8_9_1 e_1_2_8_20_1 e_1_2_8_43_1 e_1_2_8_66_1 e_1_2_8_22_1 e_1_2_8_45_1 e_1_2_8_64_1 e_1_2_8_62_1 e_1_2_8_41_1 e_1_2_8_60_1 e_1_2_8_17_1 e_1_2_8_19_1 e_1_2_8_13_1 e_1_2_8_36_1 e_1_2_8_59_1 e_1_2_8_15_1 e_1_2_8_38_1 e_1_2_8_57_1 e_1_2_8_32_1 e_1_2_8_11_1 e_1_2_8_34_1 e_1_2_8_53_1 e_1_2_8_51_1 e_1_2_8_30_1 e_1_2_8_29_1 Maluf FC (e_1_2_8_55_1) 2019; 2019 e_1_2_8_25_1 e_1_2_8_46_1 e_1_2_8_27_1 e_1_2_8_48_1 e_1_2_8_2_1 e_1_2_8_4_1 e_1_2_8_6_1 e_1_2_8_8_1 e_1_2_8_21_1 e_1_2_8_42_1 e_1_2_8_67_1 e_1_2_8_23_1 e_1_2_8_44_1 e_1_2_8_65_1 e_1_2_8_63_1 e_1_2_8_40_1 e_1_2_8_61_1 e_1_2_8_18_1 e_1_2_8_39_1 e_1_2_8_14_1 e_1_2_8_35_1 e_1_2_8_16_1 e_1_2_8_37_1 e_1_2_8_58_1 e_1_2_8_10_1 e_1_2_8_31_1 e_1_2_8_56_1 e_1_2_8_12_1 e_1_2_8_33_1 e_1_2_8_54_1 e_1_2_8_52_1 e_1_2_8_50_1 |
| References_xml | – volume: 43 start-page: 922 issue: 3 year: 2014 end-page: 929 article-title: Sample size and power calculations in Mendelian randomization with a single instrumental variable and a binary outcome publication-title: Int J Epidemiol – volume: 139 start-page: 1129 issue: 12 year: 1994 end-page: 1138 article-title: Prospective study of cigarette smoking and the risk of developing idiopathic Parkinson's disease publication-title: Am J Epidemiol – volume: 136 start-page: 732 issue: 6 year: 2017 end-page: 736 article-title: Association between Parkinson's disease and diabetes: data from NEDICES study publication-title: Acta Neurol Scand – volume: 93 start-page: 105 issue: 1 year: 2005 end-page: 117 article-title: Activation of Akt/PKB, increased phosphorylation of Akt substrates and loss and altered distribution of Akt and PTEN are features of Alzheimer's disease pathology publication-title: J Neurochem – volume: 27 start-page: 1133 issue: 8 year: 2008 end-page: 1163 article-title: Mendelian randomization: using genes as instruments for making causal inferences in epidemiology publication-title: Stat Med – volume: 293 start-page: 82 issue: 1‐2 year: 2010 end-page: 86 article-title: Case‐control study of risk of Parkinson's disease in relation to hypertension, hypercholesterolemia, and diabetes in Japan publication-title: J Neurol Sci – volume: 7 year: 2018 article-title: The MR‐base platform supports systematic causal inference across the human phenome publication-title: Elife – volume: 13 issue: 11 year: 2017 article-title: Orienting the causal relationship between imprecisely measured traits using GWAS summary data publication-title: PLoS Genet – volume: 390 start-page: 1664 issue: 10103 year: 2017 end-page: 1675 article-title: Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double‐blind, placebo‐controlled trial publication-title: Lancet – volume: 73 start-page: 1462 issue: 18 year: 2009 end-page: 1468 article-title: Autoimmune disease and risk for Parkinson disease: a population‐based case‐control study publication-title: Neurology – volume: 28 start-page: 30 issue: 1 year: 2017 end-page: 42 article-title: Sensitivity analyses for robust causal inference from Mendelian randomization analyses with multiple genetic variants publication-title: Epidemiology – volume: 96 start-page: 242 issue: 4 year: 1972 end-page: 254 article-title: Epidemiologic studies of Parkinson's disease: III. A community‐based survey publication-title: Am J Epidemiol – year: 2018 – volume: 10 start-page: 345 issue: 1 year: 2017 end-page: 361 article-title: Novel biomarkers for prediabetes, diabetes, and associated complications publication-title: Diabetes Metab Syndr Obes – volume: 10 start-page: 31 issue: 1 year: 2020 end-page: 45 article-title: Ethnic variation in the manifestation of Parkinson's disease: a narrative review publication-title: J Parkinsons Dis – volume: 19 start-page: 3127 issue: 22 year: 2000 end-page: 3131 article-title: A simple method for converting an odds ratio to effect size for use in meta‐analysis publication-title: Stat Med – volume: 15 start-page: 660 issue: 9 year: 2009 end-page: 664 article-title: Diabetes preceding Parkinson's disease onset. A case–control study publication-title: Parkinsonism Relat Disord – volume: 34 start-page: 2614 issue: 12 year: 2011 end-page: 2623 article-title: Diabetes and risk of Parkinson's disease: a systematic review and meta‐analysis publication-title: Diabetes Care – volume: 90 start-page: e1654 issue: 19 year: 2018 end-page: e1662 article-title: Diabetes mellitus and Parkinson disease publication-title: Neurology – volume: 78 start-page: 1507 issue: 19 year: 2012 end-page: 1511 article-title: Clinical features of Parkinson disease when onset of diabetes came first: a case‐control study publication-title: Neurology – volume: 113 start-page: 12473 issue: 44 year: 2016 end-page: 12477 article-title: Crosstalk between amyloidogenic proteins in type‐2 diabetes and Parkinson's disease publication-title: Proc Natl Acad Sci U S A – volume: 81 start-page: 486 issue: 958 year: 2005 end-page: 490 article-title: Diabetes and ethnic minorities publication-title: Postgrad Med J – volume: 40 start-page: 755 issue: 3 year: 2011 end-page: 764 article-title: Avoiding bias from weak instruments in Mendelian randomization studies publication-title: Int J Epidemiol – volume: 36 start-page: 244 issue: 1 year: 2007 end-page: 246 article-title: Survival‐related biases survive well publication-title: Int J Epidemiol – volume: 89 start-page: 164 issue: 3 year: 1994 end-page: 170 article-title: Risk‐factors for Parkinson's disease: case‐control study in the province of Caceres, Spain publication-title: Acta Neurol Scand – volume: 12 start-page: 73 year: 2018 article-title: The role of insulin/IGF‐1/P13K/Akt/GSK3β signaling in Parkinson's disease dementia publication-title: Front Neurosci – volume: 14 start-page: 88 issue: 2 year: 2018 end-page: 98 article-title: Global aetiology and epidemiology of type 2 diabetes mellitus and its complications publication-title: Nat Rev Endocrinol – year: 2020 article-title: Fasting plasma glucose variability in midlife and risk of Parkinson's disease: a nationwide population‐based study publication-title: Diabetes Metab – volume: 339 start-page: b2535 issue: 7716 year: 2009 article-title: Preferred reporting items for systematic reviews and meta‐analyses: the PRISMA statement publication-title: BMJ – volume: 26 start-page: 2253 issue: 12 year: 2011 end-page: 2259 article-title: Obesity, diabetes, and risk of Parkinson's disease publication-title: Mov Disord – volume: 10 start-page: 775 issue: 3 year: 2020 end-page: 789 article-title: The association between type 2 diabetes mellitus and Parkinson's disease publication-title: J Parkinsons Dis – volume: 91 start-page: 1046 issue: 10 year: 2020 end-page: 1054 article-title: Parkinson's disease determinants, prediction and gene‐environment interactions in the UK Biobank publication-title: J Neurol Neurosurg Psychiatry – volume: 145‐146 start-page: 98 year: 2016 end-page: 120 article-title: Insulin resistance and Parkinson's disease: a new target for disease modification? publication-title: Prog Neurobiol – volume: 50 start-page: 693 issue: 5 year: 2018 end-page: 698 article-title: Detection of widespread horizontal pleiotropy in causal relationships inferred from Mendelian randomization between complex traits and diseases publication-title: Nat Genet – volume: 52 start-page: 680 issue: 7 year: 2020 end-page: 691 article-title: Discovery of 318 new risk loci for type 2 diabetes and related vascular outcomes among 1.4 million participants in a multi‐ancestry meta‐analysis publication-title: Nat Genet – volume: 14 start-page: 940 year: 2020 article-title: Role of insulin in neurotrauma and neurodegeneration: a review publication-title: Front Neurosci – volume: 18 start-page: 1091 issue: 12 year: 2019 end-page: 1102 article-title: Identification of novel risk loci, causal insights, and heritable risk for Parkinson's disease: a meta‐analysis of genome‐wide association studies publication-title: Lancet Neurol – volume: 9 issue: 1 year: 2014 article-title: Diabetes and risk of Parkinson's disease: an updated meta‐analysis of case‐control studies publication-title: PLoS One – volume: 14 issue: 6 year: 2017 article-title: Estimating the causal influence of body mass index on risk of Parkinson disease: a Mendelian randomisation study publication-title: PLoS Med – volume: 77 year: 2020 – volume: 34 start-page: 1102 issue: 5 year: 2011 end-page: 1108 article-title: Diabetes and the risk of developing Parkinson's disease in Denmark publication-title: Diabetes Care – volume: 8 start-page: 92 issue: 2 year: 2011 end-page: 103 article-title: The role of mitochondria in insulin resistance and type 2 diabetes mellitus publication-title: Nat Rev Endocrinol – volume: 69 start-page: 1688 issue: 17 year: 2007 end-page: 1695 article-title: Hypertension, hypercholesterolemia, diabetes, and risk of Parkinson disease publication-title: Neurology – volume: 31 start-page: 2003 issue: 10 year: 2008 end-page: 2005 article-title: Prospective cohort study of type 2 diabetes and the risk of Parkinson's disease publication-title: Diabetes Care – volume: 44 start-page: 512 issue: 2 year: 2015 end-page: 525 article-title: Mendelian randomization with invalid instruments: effect estimation and bias detection through Egger regression publication-title: Int J Epidemiol – volume: 28 start-page: 144 issue: 2 year: 2001 end-page: 147 article-title: A case‐control study of Parkinson's disease in urban population of southern Israel publication-title: Can J Neurol Sci – volume: 19 start-page: 53 issue: 1 year: 2013 end-page: 55 article-title: Parkinson disease: associated disorders in the Norwegian population based incident ParkWest study publication-title: Parkinsonism Relat Disord – volume: 30 start-page: 842 issue: 4 year: 2007 end-page: 847 article-title: Type 2 diabetes and the risk of Parkinson's disease publication-title: Diabetes Care – volume: 31 start-page: 1518 issue: 10 year: 2016 end-page: 1526 article-title: Vascular disease and vascular risk factors in relation to motor features and cognition in early Parkinson's disease publication-title: Mov Disord – volume: 21 start-page: 446 issue: 4 year: 2006 end-page: 455 article-title: Comorbid conditions associated with Parkinson's disease: a population‐based study publication-title: Mov Disord – volume: 35 start-page: 1047 issue: 5 year: 2012 end-page: 1049 article-title: Risk of Parkinson disease onset in patients with diabetes: a 9‐year population‐based cohort study with age and sex stratifications publication-title: Diabetes Care – volume: 64 start-page: 570 issue: 4 year: 2007 end-page: 575 article-title: Relation of diabetes to mild cognitive impairment publication-title: Arch Neurol – volume: 2019 year: 2019 article-title: Analysis of the relationship between type II diabetes mellitus and Parkinson's disease: a systematic review publication-title: Parkinsons Dis – volume: 25 start-page: 603 issue: 9 year: 2010 end-page: 605 article-title: Critical evaluation of the Newcastle‐Ottawa scale for the assessment of the quality of nonrandomized studies in meta‐analyses publication-title: Eur J Epidemiol – volume: 143 start-page: 3067 issue: 10 year: 2020 end-page: 3076 article-title: Diabetes medications and risk of Parkinson's disease: a cohort study of patients with diabetes publication-title: Brain – volume: 34 start-page: 1839 issue: 12 year: 2019 end-page: 1850 article-title: Genomewide association study of Parkinson's disease clinical biomarkers in 12 longitudinal patients' cohorts publication-title: Mov Disord – volume: 95 issue: 18 year: 2016 article-title: Risk of Parkinson disease in diabetes mellitus: an updated meta‐analysis of population‐based cohort studies publication-title: Medicine (Baltimore) – volume: 72 start-page: 893 issue: 6 year: 2012 end-page: 901 article-title: Meta‐analysis of early nonmotor features and risk factors for Parkinson disease publication-title: Ann Neurol – volume: 377 start-page: 122 year: 2017 end-page: 126 article-title: Influence of diabetes mellitus on longitudinal atrophy and cognition in Parkinson's disease publication-title: J Neurol Sci – volume: 96 issue: 3 year: 2017 article-title: Increased risk of Parkinson disease with diabetes mellitus in a population‐based study publication-title: Medicine – volume: 91 start-page: e139 issue: 2 year: 2018 end-page: e142 article-title: Association between diabetes and subsequent Parkinson disease: a record‐linkage cohort study publication-title: Neurology – volume: 34 start-page: 910 issue: 4 year: 2011 end-page: 915 article-title: Diabetes and risk of Parkinson's disease publication-title: Diabetes Care – volume: 27 start-page: 974 issue: 8 year: 2012 end-page: 979 article-title: Metabolic markers or conditions preceding Parkinson's disease: a case‐control study publication-title: Mov Disord – volume: 48 start-page: 728 issue: 3 year: 2019 end-page: 742 article-title: Improving the accuracy of two‐sample summary‐data Mendelian randomization: moving beyond the NOME assumption publication-title: Int J Epidemiol – volume: 28 start-page: 166 issue: 1 year: 2019 end-page: 174 article-title: Meta‐analysis of genome‐wide association studies for body fat distribution in 694 649 individuals of European ancestry publication-title: Hum Mol Genet – volume: 12 start-page: 185 issue: 3 year: 2006 end-page: 189 article-title: Diabetes, smoking, and other medical conditions in relation to Parkinson's disease risk publication-title: Parkinsonism Relat Disord – ident: e_1_2_8_64_1 doi: 10.3233/JPD-191763 – ident: e_1_2_8_44_1 doi: 10.1002/mds.20685 – ident: e_1_2_8_56_1 doi: 10.1073/pnas.1610371113 – ident: e_1_2_8_28_1 doi: 10.1016/j.parkreldis.2005.09.004 – ident: e_1_2_8_32_1 doi: 10.1212/WNL.0000000000005771 – ident: e_1_2_8_19_1 doi: 10.1093/ije/dyu005 – ident: e_1_2_8_14_1 doi: 10.1038/s41588-020-0637-y – ident: e_1_2_8_35_1 doi: 10.2337/dc06-2011 – ident: e_1_2_8_6_1 doi: 10.1002/ana.23687 – ident: e_1_2_8_66_1 doi: 10.1093/brain/awaa262 – ident: e_1_2_8_4_1 doi: 10.1038/nrendo.2011.138 – ident: e_1_2_8_16_1 doi: 10.1371/journal.pmed.1002314 – ident: e_1_2_8_29_1 doi: 10.1002/mds.23855 – ident: e_1_2_8_24_1 doi: 10.1038/s41588-018-0099-7 – ident: e_1_2_8_31_1 doi: 10.1136/jnnp-2020-323646 – ident: e_1_2_8_7_1 doi: 10.1371/journal.pone.0085781 – volume: 2019 year: 2019 ident: e_1_2_8_55_1 article-title: Analysis of the relationship between type II diabetes mellitus and Parkinson's disease: a systematic review publication-title: Parkinsons Dis – ident: e_1_2_8_43_1 doi: 10.1111/j.1600-0404.1994.tb01655.x – ident: e_1_2_8_52_1 doi: 10.1002/mds.26698 – ident: e_1_2_8_8_1 doi: 10.1097/MD.0000000000003549 – ident: e_1_2_8_50_1 doi: 10.1111/ane.12793 – ident: e_1_2_8_60_1 doi: 10.1038/nrendo.2017.151 – ident: e_1_2_8_17_1 doi: 10.1016/S1474-4422(19)30320-5 – ident: e_1_2_8_10_1 doi: 10.1136/bmj.b2535 – ident: e_1_2_8_9_1 doi: 10.1001/jamaneurol.2019.3419 – ident: e_1_2_8_65_1 doi: 10.1016/S0140-6736(17)31585-4 – ident: e_1_2_8_33_1 doi: 10.2337/dc08-0688 – ident: e_1_2_8_26_1 doi: 10.1093/hmg/ddy327 – ident: e_1_2_8_46_1 doi: 10.1093/oxfordjournals.aje.a116960 – ident: e_1_2_8_47_1 doi: 10.1101/253690 – ident: e_1_2_8_48_1 doi: 10.2337/dc11-1511 – ident: e_1_2_8_2_1 doi: 10.1016/j.pneurobio.2016.10.001 – ident: e_1_2_8_49_1 doi: 10.1016/j.parkreldis.2012.07.003 – ident: e_1_2_8_12_1 doi: 10.1002/1097-0258(20001130)19:22<3127::AID-SIM784>3.0.CO;2-M – ident: e_1_2_8_27_1 doi: 10.1017/S0317167100052835 – ident: e_1_2_8_23_1 doi: 10.1093/ije/dyv080 – ident: e_1_2_8_58_1 doi: 10.1111/j.1471-4159.2004.02949.x – ident: e_1_2_8_39_1 doi: 10.1093/oxfordjournals.aje.a121455 – ident: e_1_2_8_40_1 doi: 10.1002/mds.25016 – ident: e_1_2_8_38_1 doi: 10.1016/j.parkreldis.2009.02.013 – ident: e_1_2_8_54_1 doi: 10.1016/j.jns.2017.04.010 – ident: e_1_2_8_5_1 doi: 10.2337/dc11-1584 – ident: e_1_2_8_61_1 doi: 10.1093/ije/dyl263 – ident: e_1_2_8_51_1 doi: 10.1212/WNL.0b013e3182553cc9 – ident: e_1_2_8_18_1 doi: 10.1002/mds.27845 – ident: e_1_2_8_59_1 doi: 10.3389/fnins.2018.00073 – ident: e_1_2_8_57_1 doi: 10.3389/fnins.2020.547175 – ident: e_1_2_8_15_1 doi: 10.1093/ije/dyr036 – ident: e_1_2_8_13_1 doi: 10.1002/sim.3034 – ident: e_1_2_8_36_1 doi: 10.1016/j.diabet.2020.08.006 – ident: e_1_2_8_22_1 doi: 10.1097/EDE.0000000000000559 – ident: e_1_2_8_63_1 doi: 10.1001/archneur.64.4.570 – ident: e_1_2_8_30_1 doi: 10.1097/MD.0000000000005921 – ident: e_1_2_8_34_1 doi: 10.2337/dc10-1922 – ident: e_1_2_8_11_1 doi: 10.1007/s10654-010-9491-z – ident: e_1_2_8_37_1 doi: 10.1016/j.jns.2010.03.002 – ident: e_1_2_8_45_1 doi: 10.1212/01.wnl.0000271883.45010.8a – ident: e_1_2_8_42_1 doi: 10.2337/dc10-1333 – ident: e_1_2_8_3_1 doi: 10.3233/JPD-191900 – ident: e_1_2_8_62_1 doi: 10.1136/pgmj.2004.029124 – ident: e_1_2_8_67_1 doi: 10.2147/DMSO.S100074 – ident: e_1_2_8_25_1 doi: 10.1093/ije/dyy258 – ident: e_1_2_8_53_1 doi: 10.1212/WNL.0000000000005475 – ident: e_1_2_8_21_1 doi: 10.1371/journal.pgen.1007081 – ident: e_1_2_8_20_1 doi: 10.7554/eLife.34408 – ident: e_1_2_8_41_1 doi: 10.1212/WNL.0b013e3181c06635 |
| SSID | ssj0011516 |
| Score | 2.661567 |
| SecondaryResourceType | review_article |
| Snippet | Background
Type 2 diabetes (T2DM) and Parkinson's disease (PD) are prevalent diseases that affect an aging population. Previous systematic reviews and... Type 2 diabetes (T2DM) and Parkinson's disease (PD) are prevalent diseases that affect an aging population. Previous systematic reviews and meta-analyses have... BackgroundType 2 diabetes (T2DM) and Parkinson's disease (PD) are prevalent diseases that affect an aging population. Previous systematic reviews and... |
| SourceID | pubmedcentral proquest pubmed crossref wiley |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 1420 |
| SubjectTerms | Aged Aging Causality Cognitive ability Diabetes Diabetes mellitus (non-insulin dependent) Diabetes Mellitus, Type 2 - complications Diabetes Mellitus, Type 2 - epidemiology Diabetes Mellitus, Type 2 - genetics Genetic analysis Genome-Wide Association Study Genomes Humans Meta-analysis Movement disorders Neurodegenerative diseases Parkinson Disease - epidemiology Parkinson Disease - genetics Parkinson's disease type 2 diabetes |
| Title | Type 2 Diabetes as a Determinant of Parkinson's Disease Risk and Progression |
| URI | https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fmds.28551 https://www.ncbi.nlm.nih.gov/pubmed/33682937 https://www.proquest.com/docview/2542191336 https://www.proquest.com/docview/2498996760 https://pubmed.ncbi.nlm.nih.gov/PMC9017318 |
| Volume | 36 |
| WOSCitedRecordID | wos000626100900001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVWIB databaseName: Wiley Online Library - Journals customDbUrl: eissn: 1531-8257 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0011516 issn: 0885-3185 databaseCode: DRFUL dateStart: 19990101 isFulltext: true titleUrlDefault: https://onlinelibrary.wiley.com providerName: Wiley-Blackwell |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1bS-QwFD6IivjirvfuuhJF0Jc6nVyalH0Sx8EHlcELzFtJmxQHtSNW_f17knaqgwoLQimFnNDcTvKd5JwvAHs8pkXCjAiVzXTIc8VCXIQLF40WZwm3RhrjL5uQFxdqOEwGM_B3EgtT80O0G25OM_x87RRcZ1XnjTT0wVSHVAkXPj3X7TLl7m2gfNAeIeBSFtcQUvgQ4QmtUEQ7bdbpxegDwvzoKPkewPoVqP_jW2X_CUsN8CRH9UhZhhlbrsDCeXO0vgpnziIllDQuMhXR-JDem7cMGRfExUj7cLH9CgX90Q65HFV3RJeGDJyrV03zsQY3_ZPr49OwuWohzDlCiJBZYaUWmjIeFYoZbXmiTCbinFuqEHPkiPtElqgow2bVrMiNSiz2s-PDY0qxdZgtx6XdBCKKLhfcRpZLtG3ySGcqKty0QoVFMNcN4GDS5mne8JC76zDu05pBmabYOqlvnQB2W9HHmnzjM6GtSceljf5hiuA4FaP9HQew0yaj5rjjEF3a8QvKYBXR2pNxFMBG3c_tXzCjQiAkA5BTI6AVcKzc0ynl6NazcyPAkjjesJp-BHxd8PS8d-U_fv2_6G9YpM6pxm8DbcHs89OL_QPz-evzqHra9gqAbzlU2zDXu-zfnP0DCMAJDQ |
| linkProvider | Wiley-Blackwell |
| linkToHtml | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1LS8QwEB5ERb34ftRnFEEvdWuatCl4EddFcXcRH-CtpE2Ki9oVq_5-J2m3uqggCD0UMqFNMpN8k8x8AdhlAc0iX3FX6ES6LBW-i4twZrLRgiRiWoVK2csmwm5X3N1FlyNwNMiFKfkh6g03Yxl2vjYGbjakG5-soU-qOKCCm_zpMYZqhPo91rxq3bbrUwRczYISRXKbJTxgFvJoo648vB59A5nfYyW_Yli7CLVm_vf7szBdgU9yXGrLHIzofB4mOtXx-gK0jVdKKKnCZAoi8SHNz4gZ0s-IyZO2KWN7BQra4x1y1SseiMwVuTThXiXVxyLctk5vTs7c6roFN2UII1xfcx1KLqnPvEz4SmoWCZXwIGWaCsQdKWI_nkTCS7BfpZ-lSkQax9pw4vlC-EswmvdzvQKEZ4eMM-1pFqJ_k3oyEV5mphbKNQK6Qwf2B50epxUXubkS4zEuWZRpjL0T295xYKcWfS4JOH4SWh-MXFzZIJZwhtMx-uCBA9t1MVqPORKRue6_oQw2ET2-MPAcWC4Huv4KVhQIhkIHwiEVqAUMM_dwSd67twzdCLJCVDhsplWB33887jSv7cvq30W3YPLsptOO2-fdizWYoibIxm4LrcPo68ub3oDx9P21V7xsVvbwASjdDAs |
| linkToPdf | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1LS8QwEB5kFfHi-1GfUQS91K1p0qbgRVwXxXVZfIC3kjYpLmpXrPr7naTd6qKCIPRQyIQ2yUzmSzLzBWCXBTSLfMVdoRPpslT4LjrhzGSjBUnEtAqVspdNhN2uuLuLemNwNMyFKfkh6g03Yxl2vjYGrp9V1vxkDX1SxQEV3ORPjzNziUwDxltX7dtOfYqA3iwoUSS3WcJDZiGPNuvKo_7oG8j8Hiv5FcNaJ9Se-d_vz8J0BT7JcaktczCm83mYvKyO1xegY1alhJIqTKYgEh_S-oyYIYOMmDxpmzK2V6CgPd4hV_3igchckZ4J9yqpPhbhtn16c3LmVtctuClDGOH6mutQckl95mXCV1KzSKiEBynTVCDuSBH78SQSXoL9Kv0sVSLSONaGE88Xwl-CRj7I9QoQnh0yzrSnWYjrm9STifAyM7VQrhHQHTqwP-z0OK24yM2VGI9xyaJMY-yd2PaOAzu16HNJwPGT0Ppw5OLKBrGEM5yOcQ0eOLBdF6P1mCMRmevBG8pgE3HFFwaeA8vlQNdfwYoCwVDoQDiiArWAYeYeLcn795ahG0FWiAqHzbQq8PuPx5eta_uy-nfRLZjstdpx57x7sQZT1MTY2F2hdWi8vrzpDZhI31_7xctmZQ4fov8Lhg |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Type+2+Diabetes+as+a+Determinant+of+Parkinson%27s+Disease+Risk+and+Progression&rft.jtitle=Movement+disorders&rft.au=Chohan%2C+Harneek&rft.au=Senkevich%2C+Konstantin&rft.au=Patel%2C+Radhika+K&rft.au=Bestwick%2C+Jonathan+P&rft.date=2021-06-01&rft.issn=1531-8257&rft.eissn=1531-8257&rft.volume=36&rft.issue=6&rft.spage=1420&rft_id=info:doi/10.1002%2Fmds.28551&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0885-3185&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0885-3185&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0885-3185&client=summon |